Accès à distance ? S'identifier sur le proxy UCLouvain
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Primary tabs
- Open access
- 1.09 M
Document type | Article de périodique (Journal article) |
---|---|
Access type | Accès libre |
Publication date | 2023 |
Language | Anglais |
Journal information | "Kidney international" - Vol. 103, no. 2, p. 391-402 (2023) |
Peer reviewed | yes |
e-issn | 1523-1755 |
Publication status | Accepté/Sous presse |
Affiliations |
UCL
- SSS/IREC/NEFR - Pôle de Néphrologie UCL - (SLuc) Service de néphrologie |
Keywords | IgA nephropathy ; glomerular disease ; glucocorticoids ; gut-associated lymphoid tissue |
Links |
Bibliographic reference | Barratt, Jonathan ; Lafayette, Richard ; Kristensen, Jens ; Stone, Andrew ; Cattran, Daniel ; et. al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.. In: Kidney international, Vol. 103, no. 2, p. 391-402 (2023) |
---|---|
Permanent URL | http://hdl.handle.net/2078.1/267736 |